Quick Answer
Biohaven Ltd. reported R&D Expense of $635.07 million for fiscal year 2025.
Biohaven Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $635.07M | -20.2% |
| 2024 | $795.87M | +113.2% |
| 2023 | $373.28M | -14.6% |
| 2022 | $437.07M | +140.8% |
| 2021 | $181.49M | +84.3% |
| 2020 | $98.46M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $141.17M | -10.4% | -23.4% |
| June 30, 2025 | $184.37M | -41.4% | -1.7% |
| March 31, 2025 | $187.58M | +20.3% | +19.0% |
| September 30, 2024 | $157.61M | +65.0% | -49.9% |
| June 30, 2024 | $314.82M | +296.0% | +101.8% |
| March 31, 2024 | $155.97M | +145.8% | +63.3% |
| September 30, 2023 | $95.52M | +80.7% | +20.2% |
| June 30, 2023 | $79.49M | -55.1% | +25.3% |
- Biohaven Ltd. showed a decrease of -20.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Biohaven Ltd.’s r&d expense has grown by 545.0% (from $98.46 million to $635.07 million).
- The most recent figure is from Biohaven Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: